An investigator-initiated, non-randomised, phase II study of combination CTLA-4 and PD-L1 blockade in combination with HER2 blockade in advanced HER2-positive breast cancers that have progressed on prior trastuzumab-based therapy (BCT 1703 DIAmOND)

Loi, Sherene ; Breast Cancer Trials (BCT)

Breast Cancer Trials (BCT) 2026

Texto completo disponível